Assembly Biosciences (NASDAQ:ASMB) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Assembly Biosciences Price Performance

Shares of ASMB opened at $0.98 on Friday. The firm has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.08. Assembly Biosciences has a 1-year low of $0.77 and a 1-year high of $2.20. The stock has a market cap of $51.56 million, a PE ratio of -0.60 and a beta of 0.74.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.03). As a group, sell-side analysts expect that Assembly Biosciences will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Several hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Assembly Biosciences in the first quarter valued at $27,000. Tower Research Capital LLC TRC grew its position in shares of Assembly Biosciences by 110.2% during the third quarter. Tower Research Capital LLC TRC now owns 17,150 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 8,992 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Assembly Biosciences by 15,633.0% during the first quarter. JPMorgan Chase & Co. now owns 14,789 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 14,695 shares during the period. UBS Group AG raised its holdings in Assembly Biosciences by 110.0% in the fourth quarter. UBS Group AG now owns 24,007 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 12,576 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Assembly Biosciences in the first quarter worth approximately $32,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.